What Genecis does

Genecis Bioindustries is a Toronto-based climate biotechnology company that converts organic waste into biodegradable polyhydroxyalkanoate (PHA) plastics using a proprietary recombinant bacteria fermentation platform. Founded in 2016 by CEO Luna Yu, the company operates a 240-litre pilot plant and is commissioning a 3,000-litre demo facility, with an architecture designed to integrate onto existing biogas plant infrastructure rather than rely on purpose-built facilities. Its PHA output is tunable for rigid and flexible applications and is positioned as a drop-in substitute for petroleum-based plastics that fully biodegrades in roughly 12 months across land and marine environments.

The company sells to enterprise customers in single-use plastics, packaging, automotive, textiles, and medical device end-markets through a B2B go-to-market combining direct enterprise sales, custom polymer formulation services, rapid product development collaborations, and co-branding partnerships. Named strategic relationships include StormFisher (biogas infrastructure integration for commercial-scale production in London, Ontario), Helian Polymers (PHA resin development for 3D printing and biomedical applications), Sodexo (food services), and Novo Nordisk (medical/health applications). Production scale-up is staged, with the technology validated by a third-party lab at 1,000L.

Genecis is venture-capital-backed, having raised a US$7 million Series A in August 2022 led by Khosla Ventures and BDC Capital's Cleantech Practice, plus a US$3 million Silicon Valley Bank credit facility, with a subsequent US$3.25 million exempt offering in early 2023. Reported commercial traction includes $6 million in closed deals against a $55 million LOI pipeline. Revenue is not publicly disclosed and the company remains at pilot scale with 15 employees, indicating a pre-commercial or early-commercial revenue profile at present.

Name

Genecis

Legal name

Genecis Bioindustries Inc.

Website

https://genecis.co

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Genecis Bioindustries is a Toronto-based climate biotech company that uses proprietary recombinant bacteria fermentation to convert organic waste into biodegradable PHA bioplastics, serving enterprise customers in packaging, single-use plastics, automotive, textiles, and medical sectors through direct B2B sales and co-development partnerships.

Ownership category

akta.pro rank

Product category

Biodegradable Bioplastics

NAICS

Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing (3252)

SIC

Industrial Organic Chemicals (2860)

akta.pro primary industry

Bio-based & Biodegradable Polymer Resin Manufacturing (PLA, PHA, PBS, starch blends) (IMANAAAG)

akta.pro secondary industries

Bio-based Polymers & Bioplastics (e.g., PLA, PHA, bio-PE/PP/PET, PBS) (EUAAAIAC), Biodegradable Packaging Materials (films, trays, foams) (IMAEAOAB), Bio-based Platform & Commodity Chemicals (e.g., bio-ethylene, bio-propylene, bio-BTX, bio-methanol) (EUAAAIAA), Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids) (EUAAAIAL), Bio-Based & Biodegradable Compounds (PLA/PHA/Starch Blends) (IMANABAF)

Keywords

• Bioplastics manufacturing
• Polyhydroxyalkanoate (PHA)
• Organic waste valorization
• Synthetic biology platform
• Compostable biopolymers

Headquarters

HQ city

Scarborough

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Infrastructure

Revenue model

1. PHA Bioplastics Sales: Genecis develops and sells biodegradable PHA plastics to manufacturers for use in packaging, textiles, automotive, medical and other applications. Products include custom polymer formulations and co-branded products.
2. Polymer Development Services: Custom polymer formulation services where Genecis works with partners to develop ideal polymer formulations for current or new product lines. Includes technical validation and product development.
3. Rapid Product Development: Collaborative product development services to help partners bring PHA-based products to market faster. Includes design, testing, and launch support.
4. Co-Branding Partnership: Long-term co-branding partnerships where Genecis provides PHA materials and technical expertise for partners to create and market sustainable products under joint branding.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

Genecis Bioindustries produces biodegradable polyhydroxyalkanoate (PHA) bioplastics by fermenting organic food waste using proprietary engineered bacteria. The company sells PHA bioplastic pellets and custom-formulated compounds to manufacturers in packaging, automotive, textile, and medical sectors, and offers polymer development and co-branding services for sustainable product lines.

Product overview

Genecis is a climate biotech company offering a unified platform centered on PHA (Polyhydroxyalkanoate) bioplastics produced through proprietary bacterial fermentation of organic waste. The product portfolio includes four application-specific PHA formulations: Single-Use Plastics (replacement for packaging and bags), Automotive & Textiles (rigid and flexible formulations), Packaging (compostable solutions), and Medical Tools & Products (medical-grade implants and equipment). The service layer consists of three modules—Polymer Development (custom resin formulation), Rapid Product Development (6-month product validation and launch), and Co-Branding (market differentiation partnership)—enabling businesses to de-risk their transition to sustainable materials. The company also commercialized Folly, a hair health gummy brand leveraging proprietary microencapsulation technology derived from its parent company's biotech capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• PHA Bioplastics Fully biodegradable polyhydroxyalkanoate (PHA) bioplastic pellets and compounds produced from organic food waste via proprietary fermentation. Sold to manufacturers in packaging, automotive, textile, and medical sectors as a compostable alternative to petroleum-based plastics.
• Polymer Development Services

Quantifiable outcome

• PHA biodegrades completely within 12 months in natural environments, compared to oil-based plastics that take up to 1000 years and leave microplastics
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Helian PolymerscoreStrategic or Co-development Partner · 16 December 2022Strategic collaboration to develop PHA-based resin formulations for high-value applications including 3D printing filaments and biomedical applications. Combines Genecis' waste-to-PHA capabilities with Helian's PHA material development expertise. Both companies will develop various formulations leveraging their respective strengths in bioplastics.
• StormFishercoreStrategic or Co-development Partner · 4 August 2022Biogas plant operator in London, Canada where Genecis will integrate its technology for the first commercial-scale production. This partnership enables Genecis to piggyback onto existing biogas infrastructure for rapid scaling.
• SodexosupportingStrategic or Co-development PartnerEarly corporate partner that shared Genecis' vision of sustainable production and waste reduction. One of the first major companies to work with Genecis.
• Novo NordisksupportingStrategic or Co-development PartnerAccepted Genecis into their Innovation Challenge program, recognizing the company's innovative approach to sustainability in the health and wellness sector.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Novamont: Italian producer of Mater-Bi compostable bioplastics (starch/PBAT blends); established competitor in the same compostable-packaging end market that Genecis targets.
• CJ CheilJedang: South Korean conglomerate producing PHACT PHA biopolymers; much larger fermentation footprint than Genecis with established industrial customer base.
• NatureWorks: Producer of Ingeo PLA biopolymers; the largest commercial bioplastic incumbent and direct substitute for Genecis PHA in packaging applications.
• BASF: Global chemical major producing Ecovio (PLA/PBAT blend); competitor and award-giver (BASF Innovation Pitch Series) targeting same single-use and compostable packaging market.

Direct peers

• Danimer Scientific: Publicly listed US-based PHA (Nodax) producer and direct competitor; targets same biodegradable packaging, foodservice, and consumer goods applications as Genecis.
• RWDC Industries: Singapore/US PHA (Solon) producer using bacterial fermentation of plant oils; closest technology and product analog to Genecis's PHA platform.
• Kaneka: Japanese chemical company producing Kaneka PHBH PHA biopolymers; competing directly with Genecis in packaging and single-use plastic replacement markets.
• TianAn Biopolymer: Chinese PHB/PHA polymer producer (Enmat) supplying biodegradable plastics for packaging and consumer goods; similar product portfolio to Genecis.

Emerging players

• Mango Materials: US startup producing PHA from methane/waste gases using engineered microbes; adjacent waste-to-PHA technology approach comparable to Genecis's waste-feedstock model.
• Newlight Technologies: US company producing AirCarbon PHA from greenhouse gases; a direct microbial-PHA competitor at similar maturity to Genecis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/genecisbioindustries
• Xx.com/gbioindustries
• Facebookfacebook.com/genecistech

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds11 records

Investors29 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genecis